ICU Medical, Inc. - 10-Q Filing Summary
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for ICU Medical, Inc., a Delaware corporation engaged in the development, manufacturing, and marketing of disposable medical devices. The report covers the quarterly and nine-month periods ended September 30, 2005. The company operates principally in one business segment, focusing on intravenous (I.V.) therapy systems and critical care devices.
Key Financial Metrics
(All amounts in thousands, except per share data)
| Metric | Three Months Ended 9/30/05 | Nine Months Ended 9/30/05 | Nine Months Ended 9/30/04 |
|---|---|---|---|
| Total Revenue | $46,524 | $114,302 | $60,366 |
| Net Sales | $46,121 | $111,900 | $58,166 |
| Gross Profit | $19,276 | $50,834 | $30,998 |
| Gross Margin (of Net Sales) | 41.8% | 45.4% | 53.3% |
| Operating Income | $8,288 | $20,539 | $9,316 |
| Net Income | $5,807 | $14,963 | $6,514 |
| Diluted EPS | $0.39 | $1.00 | $0.43 |
| Cash from Operations (9mo) | $19,513 | ||
| Cash & Liquid Investments (9/30/05) | $78,123 | ||
| Total Debt | None reported (No long-term debt) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 182% for the quarter and 89% for the nine-month period compared to the prior year. This surge is primarily driven by the May 1, 2005, acquisition of Hospira's Salt Lake City manufacturing facility and the commencement of a 20-year Manufacturing, Commercialization and Development Agreement (MCDA).
- Customer Concentration: Sales to Hospira, Inc. now represent 77% of net sales for the quarter and 72% for the nine-month period, up from 56% and 57% respectively in the prior year.
- Margin Compression: Gross margins declined to 41.8% (quarter) and 45.4% (nine months) from 37% and 53.3% in the prior year periods. Management attributes this to the inclusion of lower-margin critical care products manufactured under the new MCDA (approx. 21% margin) compared to traditional high-margin products (approx. 53% margin).
- Balance Sheet: Accounts receivable increased significantly to $25.7 million from $8.9 million at year-end 2004, largely due to new receivables from Hospira under the MCDA. Inventory increased to $13.5 million, reflecting the acquisition of Hospira's inventory and increased raw materials for the new facility.
Outlook, Risks, and Management Commentary
- Strategic Shift: The company is transitioning from a product-centered model to a low-cost manufacturer of custom I.V. systems and critical care devices. The MCDA with Hospira is central to this strategy, though it increases dependence on a single customer.
- Manufacturing Relocation: The company is relocating molding and automated assembly from San Clemente and Connecticut to Salt Lake City, and moving manual assembly to Mexico. This process is expected to be completed by early 2007 and carries risks of production interruption.
- Legal Proceedings: The company settled a patent infringement suit with B. Braun Medical Inc. in April 2005. It is currently pursuing litigation against Alaris Medical Systems (a Cardinal Health subsidiary) for patent infringement regarding SmartSite valves.
- Accounting Changes: The company plans to adopt SFAS 123(R) regarding share-based payments on January 1, 2006, using the modified prospective method.
- Risks: Key risks include dependence on Hospira for the majority of sales, potential price erosion, competition from larger firms, and the successful integration of the new Salt Lake City facility.
Investor Verification Checklist
- Hospira Dependency: Verify the stability of the MCDA agreement and Hospira's ability to maintain market share, given that 72-77% of revenue is tied to this single customer.
- Margin Sustainability: Assess whether the company can achieve the projected cost savings in the Salt Lake City facility to improve the currently low margins on MCDA products.
- Integration Risks: Monitor the progress of the manufacturing relocation to Salt Lake City and Mexico for potential disruptions or cost overruns.
- Patent Litigation: Track the outcome of the ongoing lawsuit against Alaris Medical Systems, as a loss could impact market share and pricing power.
- Working Capital: Review the significant increase in accounts receivable ($16.8M increase) to ensure collectibility remains strong despite the shift in customer mix.